Cure My Disease

Don't miss your cure!

Home News Browse Soon ready About
Log in / Sign up
← Back to home

Fujian Akeylink Biotechnology Co., Ltd.

Clinical trials sponsored by Fujian Akeylink Biotechnology Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

  • New drug combo aims to silence hepatitis b virus Results expected Oct 2026 (estimated)
  • New pill could help hepatitis b patients who Don't respond to standard care Results expected Dec 2026 (estimated)
Browse trials soon ready across all sponsors →
Trials to join now! 2 Not yet recruiting 1
Sort by
  • New combo therapy aims to keep hepatitis b in check

    Disease control Not yet recruiting

    This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep …

    Phase 3 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control

    Last updated Jun 27, 2026 12:32 UTC

Cure My Disease

Helping patients find clinical trials that match their disease.

Why was Cure my disease built?

Explore

Home News Browse Glossary About Terms of use Contact us

This is a site from Cyber and Space